Research programme: facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies

Drug Profile

Research programme: facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies

Alternative Names: Facioscapulohumeral muscular dystrophy therapeutics - Evotec AG/Facio Therapies; FSHD therapeutics - Evotec AG/Facio Therapies

Latest Information Update: 14 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Evotec AG; Facio Therapies
  • Class Small molecules
  • Mechanism of Action DUX4 protein inhibitors; SMCHD1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Facioscapulohumeral muscular dystrophy

Most Recent Events

  • 29 Apr 2015 Evotec AG and Facio Therapies agree to co-develop Facioscapulohumeral muscular dystrophy therapeutics
  • 29 Apr 2015 Early research in Facioscapulohumeral muscular dystrophy in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top